2 Twohig J., Kulik L., Haluszczak C., ReuterJ., Rossbach A., Bull M., Holers V.M., and Marchbank K.J. Defective B cell ontogeny and immune response in human complement receptor 2 (CR2, CD21). transgenic mice is partially recovered in the absence of C3. Mol Immunol. 2007, 44:3434-44.
I.Y.Pappworth, L.Kulik, C.Haluszczak, J.W.Reuter, V.M.Holers and K.J.Marchbank. Increased B cell deletion and significantly reduced auto-antibody titre due to premature expression of human complement receptor 2 (CR2, CD21).Mol Immunol. In press
L.Kulik, S.D.Fleming, C.Moratz, J.W.Reuter, A.Novikov, K.Chen, K.A.Andrews, A.Markaryan, R.J.Quigg, G.J.Silverman¶, G.C.Tsokos and V.M.Holers. Pathogenic Natural Antibodies Recognizing Annexin IV Are Required to Develop Intestinal Ischemia-Reperfusion Injury. J.Immun. Accepted
Twohig JP, Pappworth IY, Sivasankar B, Kulik L, Bull M, Holers VM, Wang EC, Marchbank KJ. Defective B cell ontogeny and humoral immune response in mice prematurely expressing human complement receptor 2 (CR2, CD21) is similar to that seen in aging wild type mice. Mol Immunol. 2009
Renner B, Amura CR, Kulik L, Ljubanovic D, Glogowska MJ, Botto M, Takahashi K, Stahl GL, Carroll MC, Holers VM, and Thurman JM. B Cell Subsets Contribute to Both Renal Injury and Renal Protection after Ischemia/Reperfusion- Submitted
Renner B, Strassheim D, Amura CR, Kulik L, Ljubanovic D, Glogowska MJ, Takahashi K, Carroll MC, Holers VM, Thurman JM. B cell subsets contribute to renal injury and renal protection B cell subsets contribute to renal injury and renal protection after ischemia/reperfusion., J Immunol. 2010 Oct 1;185(7):4393-400
Kulik L, Chen K, Huber BT, Holers VM. Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists.Mol Immunol. 2011 Mar;48(6-7):883-94.
Willis VC, Gizinski AM, Banda NK, Causey CP, Knuckley B, Cordova KN, Luo Y, Levitt B, Glogowska M, Chandra P, Kulik L, Robinson WH, Arend WP, Thompson PR, Holers VM.N-α-Benzoyl-N5-(2-Chloro-1-Iminoethyl)-L-Ornithine Amide, a Protein Arginine Deiminase Inhibitor, Reduces the Severity of Murine Collagen-Induced Arthritis.J Immunol. 2011 Feb 23
1. Weckbach S., Neher M., Losacco J., Bolden A., Kulik L., Flierl M., Bell S., Holers VM., Stahel P. Challenging the role of adaptive immunity in neurotrauma: Rag1-/- mice lacking mature B and T cells do not show neuroprotection after closed head injury. J Neurotrauma. 2012, in press
2. Elvington A, Atkinson C, Kulik L, Zhu H, Yu J, Kindy MS, Holers VM, Tomlinson S. Pathogenic Natural antibodies propagate cerebral injury following ischemic stroke in mice.. J Immunol. 2012;.188: 1460-1468
3. Willis VC, Gizinski AM, Banda NK, Causey CP, Knuckley B, Cordova KN, Luo Y, Levitt B, Glogowska M, Chandra P, Kulik L, Robinson WH, Arend WP, Thompson PR, Holers VM. N-a-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis., J Immunol. 2011; 186:4396-4404
IgM Contributes to Glomerular Injury in FSGS Strassheim D, Renner B, Panzer S, Fuquay R, Kulik L, Ljubanovic D, Holers VM, Thurman JM. J Am Soc Nephrol. 2013
Novel mouse anti-mouse monoclonal antibodies that block either the ligand or receptor member of the CR2-C3d interaction pair impair antigen-specific humoral immune responses to model antigens. Liudmila Kulik1, Joshua M. Thurman1, Jonathan P. Hannan1, Stephen Tomlinson2, V. Michael Holers. XXIV International Complement Workshop
Detection of complement activation using epitope-specific monoclonal antibodies to C3d. J. M. Thurman, L. Kulik, H.Orth, M.Wong, B. Renner, S. A. Sargsyan, L. M. Mitchell, D. E. Hourcade, J.P. Hannan, J. M. Kovacs, B. Coughlin, A. S. Woodell, M. C. Pickering, B. Rohrer, V. M. Holers. JCI.
Oxidative Stress Sensitizes RPE Cells To Complement-Mediated Injury In A Natural Antibody-, Lectin Pathway- And Phospholipid Epitope-Dependent Manner. K. Joseph, L. Kulik, B.Coughlin, M. Bandyopadhyay, K. Kunchithapautham, S. Thiel, N.M. Thielens, V. M. Holers, and B. Rohrer, JBC
Thurman JM, Kulik L, Orth H, Wong M, Renner B, Sargsyan SA, Mitchell LM, Hourcade DE, Hannan JP, Kovacs JM, Coughlin B, Woodell AS, Pickering MC, Rohrer B, Holers VM. Detection of complement activation using monoclonal antibodies against C3d. J Clin Invest. 2013 May 1;123(5):2218-30. PubMed PMID: 23619360
Joseph K, Kulik L, Coughlin B, Kunchithapautham K, Bandyopadhyay M, Thiel S, Thielens NM, Holers VM, Rohrer B. Oxidative stress sensitizes retinal pigmented epithelial (RPE) cells to complement-mediated injury in a natural antibody-, lectin pathway-, and phospholipid epitope-dependent manner. J Biol Chem. 2013 May 3;288(18):12753-65. PubMed PMID: 23493397
Kulik L, Hewitt FB, Willis VC, Rodriguez R, Tomlinson S, Holers VM. A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease. Mol Immunol. 2015 Feb;63(2):479-88. PubMed PMID: 25457881
Neher MD, Rich MC, Keene CN, Weckbach S, Bolden AL, Losacco JT, Patane J, Flierl MA, Kulik L, Holers VM, Stahel PF. Deficiency of complement receptors CR2/CR1 in Cr2?/? mice reduces the extent of secondary brain damage after closed head injury. J Neuroinflammation. 2014 May 24;11:95. PubMed PMID: 24885042
Panzer SE, Laskowski J, Renner B, Kulik L, Ljubanovic D, Huber KM, Zhong W, Pickering MC, Holers VM, Thurman JM. IgM exacerbates glomerular disease progression in complement-induced glomerulopathy. Kidney Int. 2015 Sep;88(3):528-37. PubMed PMID: 25945405
Atkinson C, Qiao F, Yang X, Zhu P, Reaves N, Kulik L, Goddard M, Holers VM, Tomlinson S. Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation. 2015 Mar 31;131(13):1171-80. PubMed PMID: 25825397
Holers VM, Tomlinson S, Kulik L, Atkinson C, Rohrer B, Banda N, Thurman JM. New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Semin Immunol. 2016 Jun;28(3):260-7. PubMed PMID: 27282113
International Complement Workshop.
Treatment of a Murine Model of Human Lupus with a mAb that Blocks Binding of C3d to Receptors Decreases Anti-DNA Autoantibodies and Proteinuria:
Implications for the CR2:C3d Interaction as a Therapeutic Target in Lupus/Autoimmune Diseases
ALR. Treatment of MRL/lpr mice with a mAb blocking binding of C3d to its receptors decreases anti-DNA autoantibodies and proteinuria: support for targeting the CR2:C3d interaction as a therapeutic strategy in SLE
LUPUS 21st century. Treatment of MRL/lpr Mice with a mAb Blocking Binding of C3d to Its Receptors Decreases Anti-DNA Autoantibodies and Proteinuria: Support for Targeting the CR2:C3d Interaction as a Therapeutic Strategy in SLE
Narang A, Qiao F, Atkinson C, Zhu H, Yang X, Kulik L, Holers VM, Tomlinson S.
J Neuroinflammation. 2017 Jun 19;14(1):120
Natural IgM antibodies that bind neoepitopes exposed as a result of spinal cord injury , drive secondary injury by activating complement.
He YG, Pappworth IY, Rossbach A, Paulin J, Mavimba T, Hayes C, Kulik L, Holers VM, Knight AM, Marchbank KJ.
Immunobiology. 2018 Jan;223(1):125-134
A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice.
He YG, Pappworth IY, Rossbach A, Paulin J, Mavimba T, Hayes C, Kulik L, Holers VM, Knight AM, Marchbank KJ. A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice. Immunobiology. 2018 Jan;223(1):125-134. PubMed PMID: 29017821
Kulik L, Laskowski J, Renner B, Woolaver R, Zhang L, Lyubchenko T, You Z, Thurman JM, Holers VM. Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus. J Immunol. 2019 Dec 15;203(12):3136-3147. PubMed PMID: 31732528
Goetz L, Laskowski J, Renner B, Pickering MC, Kulik L, Klawitter J, Stites E, Christians U, van der Vlag J, Ravichandran K, Holers VM, Thurman JM. Complement factor H protects mice from ischemic acute kidney injury but is not critical for controlling complement activation by glomerular IgM. Eur J Immunol. 2018 May;48(5):791-802. PubMed PMID: 29389016
Banda NK, Tomlinson S, Scheinman RI, Ho N, Ramirez JR, Mehta G, Wang G, Vu VP, Simberg D, Kulik L, Holers VM. C2 IgM Natural Antibody Enhances Inflammation and Its Use in the Recombinant Single Chain Antibody-Fused Complement Inhibitor C2-Crry to Target Therapeutics to Joints Attenuates Arthritis in Mice. Front Immunol. 2020;11:575154. PubMed PMID: 33178202
Li C, Patel K, Tu Z, Yang X, Kulik L, Alawieh A, Allen P, Cheng Q, Wallace C, Kilkenny J, Kwon J, Gibney B, Cantu E, Sharma A, Pipkin M, Machuca T, Emtiazjoo A, Goddard M, Holers VM, Nadig S, Christie J, Tomlinson S, Atkinson C. A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant injury. Am J Transplant. 2020 Nov 19. [Epub ahead of print] PubMed PMID: 33210808
Trachtman H, Laskowski J, Lee C, Renner B, Feemster A, Parikh S, Panzer SE, Zhong W, Cravedi P, Cantarelli C, Kulik L, You Z, Satchell S, Rovin B, Liu F, Kalled SL, Holers VM, Jalal D, Thurman JM. Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome. Am J Physiol Renal Physiol. 2021 Oct 1;321(4):F505-F516. PubMed PMID: 34459222
Li C, Patel K, Tu Z, Yang X, Kulik L, Alawieh A, Allen P, Cheng Q, Wallace C, Kilkenny J, Kwon J, Gibney B, Cantu E, Sharma A, Pipkin M, Machuca T, Emtiazjoo A, Goddard M, Holers VM, Nadig S, Christie J, Tomlinson S, Atkinson C. A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant injury. Am J Transplant. 2021 Jun;21(6):2067-2078. PubMed PMID: 33210808
Wahid AA, Dunphy RW, Macpherson A, Gibson BG, Kulik L, Whale K, Back C, Hallam TM, Alkhawaja B, Martin RL, Meschede I, Laabei M, Lawson ADG, Holers VM, Watts AG, Crennell SJ, Harris CL, Marchbank KJ, van den Elsen JMH. Insights Into the Structure-Function Relationships of Dimeric C3d Fragments. Front Immunol. 2021;12:714055. PubMed PMID: 34434196
Gordon L, Mabbott N, Wells J, Kulik L, Juleff N, Charleston B, Perez-Martin E. Foot-and-mouth disease virus localisation on follicular dendritic cells and sustained induction of neutralising antibodies is dependent on binding to complement receptors (CR2/CR1). PLoS Pathog. 2022 May;18(5):e1009942. PubMed PMID: 35512014
Whelan R, Feemster A, Laskowski J, Renner B, Kulik L, Poppelaars F, Lee C, Holers VM, Thurman JM. Female but Not Male Mice Deficient in Soluble IgM Are Susceptible to Chemically Induced Glomerular Injury. J Immunol. 2023 Oct 15;211(8):1240-1248. PubMed PMID: 37682538
Renner B, Poppelaars F, Laskowski J, Serkova NJ, Kulik L, Holers VM, Thurman JM. Noninvasive Detection of iC3b/C3d Deposits in the Kidney Using a Novel Bioluminescent Imaging Probe. J Am Soc Nephrol. 2023 Jul 1;34(7):1151-1154. PubMed PMID: 36995143
Kulik L., Renner B., Laskowski J., Thurman J.M., Holers V.M. Highly pathogenic natural monoclonal antibody B4-IgM recognizes a post-translational modification comprised of acetylated N-terminal methionine followed by aspartic or glutamic acid. Mol Immunol.
PMID: 37018938